Docetaxel weekly regimen in conjunction with RF hyperthermia for pretreated locally advanced non-small cell lung cancer: a preliminary study
2007

Docetaxel and RF Hyperthermia for Lung Cancer

Sample size: 29 publication Evidence: moderate

Author Information

Author(s): Jiang Zhu, Yan Wang, Ming Jiang, Yu Yang

Primary Institution: Cancer Center of West China (Hua Xi) Hospital, Si Chuan University

Hypothesis

To evaluate the feasibility and therapeutic effect of chemotherapy combined with regional radio frequency hyperthermia for pretreated locally advanced non-small cell lung cancer.

Conclusion

The combination of chemotherapy and regional hyperthermia was safe and showed promising tumor control and survival rates.

Supporting Evidence

  • The overall response rate was 25.9%.
  • The tumor control rate was 66.6%.
  • Median progression free survival was 4 months.
  • Median overall survival was 11 months.

Takeaway

Doctors combined a special heat treatment with chemotherapy to help patients with lung cancer, and it seemed to work pretty well.

Methodology

29 patients received up to 4 cycles of chemotherapy and 32 sessions of RF hyperthermia, with survival and toxicity evaluated.

Limitations

The study had a small sample size and was preliminary, requiring further research.

Participant Demographics

{"median_age":57,"gender_distribution":{"male":21,"female":8},"histological_subtype":{"squamous_carcinoma":11,"adenocarcinoma":18},"stage_distribution":{"IIIa":12,"IIIb":17}}

Statistical Information

Confidence Interval

{"PFS":"1.9–6.1 months","OS":"9.3–12.8 months"}

Digital Object Identifier (DOI)

10.1186/1471-2407-7-189

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication